Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 6/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664122 | 1.00 | ALOX15 (0.47) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| SCHEMBL23069553 | 1.00 | ALOX15 (0.47) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| Foslevodopa SCHEMBL17685899 | 0.89 | SLC7A5 (0.61) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| SCHEMBL17693592 | 0.89 | ALOX15 (0.47) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| Foslevodopa SCHEMBL17685900 | 0.89 | SLC7A5 (0.61) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| Foslevodopa SCHEMBL29927312 | 0.89 | SLC7A5 (0.61) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| SCHEMBL17685876 | 0.85 | ALDH1A1 (0.52) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| SCHEMBL30946599 | 0.85 | ALDH1A1 (0.52) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| SCHEMBL17685877 | 0.85 | ALDH1A1 (0.52) | ALOX15LCKSLC7A5KDM4EUSP2 | |
| SCHEMBL7295205 | 0.84 | ALOX15 (0.43) | ALOX15LCKSLC7A5KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | claimed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | claimed |
| CN-114727973-A | Liquid compositions comprising L-dopa amino acid conjugates and uses thereof | 纽罗德姆有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | claimed |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4460289-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | Neuroderm, Ltd. (IL) | 2024-11-13 | — | — | EP | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| CN-114727973-A | Liquid compositions comprising L-dopa amino acid conjugates and uses thereof | 纽罗德姆有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | ALOX15 1222/4885LCK 4761/4885SLC7A5 673/4885 |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | DAO, DDC, AADAT | ALOX15 213/4885LCK 3708/4885SLC7A5 80/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | ALOX15 1146/4885LCK 4628/4885SLC7A5 981/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | ALOX15 902/4885LCK 4506/4885SLC7A5 1195/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | ALOX15 1210/4885LCK 4754/4885SLC7A5 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.